Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic test kits in the United States. The company offers rapid diagnostic tests, such as the CoVid-19 test, whole blood Ebola test, whole blood Zika test, whole blood rapid TB test, and various other tests for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, and other vector-borne diseases. Global WholeHealth Partners Corporation was incorporated in 2013 and is based in San Clemente, California.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E. Editor's note: P/CR i
Buy
Sell